A recent Elsevier survey of 100 urologists and 100 medical oncologists who treat patients with castration-resistant prostate cancer (CRPC) identified a knowledge gap in their understanding of the recently approved therapies and what information they wanted to know concerning how and when to properly prescribe these treatments.
The survey also revealed that approximately 30% of urologists had yet to prescribe one of the newly approved therapies. In response to these findings, a panel of topic experts in the fields of oncology, nursing, and specialty pharmacy convened for a roundtable discussion and to develop a companion summary article to provide a knowledge-based perspective for physicians treating patients with metastatic CRPC (http://prostatecancer.urologiconcology.org/). These participating oncology experts discussed how CRPC is defined, how the newly approved agents should be sequenced in the management of a typical patient with CRPC, and the clinical considerations regarding the role of specialty pharmacy providers and nurse practitioners as patient advocates when selecting these therapies for treating metastatic CRPC.
Written by:
Taplin ME, Berry WR, Casey AM, Aslo A. Are you the author?
Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA.
Reference: Hosp Pract (1995). 2013 Oct;41(4):81-2.
doi: 10.3810/hp.2013.10.1084
PubMed Abstract
PMID: 24145593
UroToday.com mCRPC Treatment Section
